Drugs / Anruikefen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07330063 | Dec 2025 → Jun 2026 overdue | — | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anruikefen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07330063 ↗ |
| Action | Activate | “peripherally highly selective kappa receptor agonist” NCT07330063 ↗ |
| Route | Intravenous | “via intravenous bolus injection” NCT07330063 ↗ |